Novartis antitrust lawyer sceptical of innovation review in pharma mergers
The head of Novartis’ antitrust legal team yesterday said innovation considerations while reviewing mergers in the pharmaceutical industry may be a solution in search of a problem.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now